18:56 , Jun 17, 2019 |  BC Extra  |  Company News

Array takeout buoys biotechs, strengthens Pfizer in targeted oncology

Public biotechs got a boost Monday on the strength of Pfizer's $11.4 billion buyout of Array, signaling that continued M&A interest in the sector can help reverse the loss in momentum that has led to...
14:18 , May 20, 2019 |  BC Innovations  |  Distillery Techniques

RB1 alterations predict survival in mCRPC patients treated with Zytiga or Xtandi

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling Alterations in RB1 could help predict survival in mCRPC patients treated with Zytiga or Xtandi. In 429 patients with mCRPC, analysis of whole-exome sequencing, gene expression, histopathology, survival and...
19:01 , Apr 26, 2019 |  BC Extra  |  Company News

Amgen, Astellas join list of biopharmas paying for alleged co-pay charity kickbacks

The Department of Justice said Thursday that Amgen and Astellas have agreed to pay $124.8 million combined to settle allegations of kickbacks to charitable patient assistance programs. Astellas Pharma Inc. (Tokyo:4503) will pay $100 million...
22:01 , Mar 15, 2019 |  BioCentury  |  Product Development

Broadening the PARP playing field

With its latest clinical win for Lynparza, AstraZeneca is leading the field in stretching the use of PARP inhibitors beyond tumors that carry BRCA mutations. The results highlight one piece of a broader strategy companies...
22:14 , Mar 1, 2019 |  BioCentury  |  Product Development

Prostate cancer disrupted

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades. The launch of generic abiraterone means next generation anti-androgens...
19:49 , Feb 15, 2019 |  BC Week In Review  |  Clinical News

Xtandi reduces radiographic PFS by 61% in metastatic hormone-sensitive prostate cancer

Astellas Pharma Inc. (Tokyo:4503) and Pfizer Inc. (NYSE:PFE) reported that Xtandi enzalutamide plus androgen deprivation therapy (ADT) reduced the risk of radiographic progression or death, the primary endpoint, by 61% vs. ADT alone in the...
15:59 , Feb 6, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer In vitro and mouse studies identified a chromenecarbaldehyde-based IRE1 inhibitor that could help treat prostate cancer. Optimization and in vitro binding assays of a family of tool compound IRE1 inhibitors yielded a...
16:04 , Feb 5, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture and mouse studies identified an aryloxytetramethylcyclobutane-based degrader of androgen receptor that could help treat prostate cancer. Chemical synthesis and testing in three prostate cancer cells lines of analogs of a...
13:10 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture and mouse studies suggest inhibiting Hsp70 could help treat prostate cancer resistant to Xtandi enzalutamide and/or Zytiga abiraterone acetate. In human prostate cancer cell lines, high Hsp70 levels were associated...
18:25 , Nov 9, 2018 |  BC Week In Review  |  Company News

Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214

Pfizer Inc. (NYSE:PFE) will combine NKTR-214 from Nektar Therapeutics Inc. (NASDAQ:NKTR) with the pharma's marketed drugs Xtandi enzalutamide, Talzenna talazoparib and Bavencio avelumab to treat prostate cancer, testing the biotech's hypothesis that stimulation of IL-2...